BioVie completes enrollment in Long COVID trial as need for treatments grows

BioVie CEO Cuong Do joined Steve Darling from Proactive to announce the successful completion of patient enrollment for the company’s ADDRESS-LC Phase 2 clinical study evaluating its drug candidate bezisterim for the treatment of neurological symptoms associated with Long COVID. The study marks an important milestone for the company and is fully funded through a grant from the U.S. Department of Defense, helping advance the program without additional financing pressures tied directly to the trial. Do highlighted the growing healthcare challenge posed by Long COVID, which continues to affect millions of individuals long after their initial infection. According to estimates, approximately 15 million adults in the United States reported experiencing Long COVID between 2022 and 2023, with roughly 3.8 million indicating that symptoms significantly interfered with their daily activities and quality of life. The persistence of symptoms has created an increasing need for effective treatme...